Measuring Biomarker Response to AMP-514 in Blood Samples From Patients With Solid Tumors Undergoing Radiotherapy - Trial NCT02153151
Access comprehensive clinical trial information for NCT02153151 through Pure Global AI's free database. This phase not specified trial is sponsored by Sidney Kimmel Cancer Center at Thomas Jefferson University and is currently Completed. The study focuses on Unspecified Adult Solid Tumor, Protocol Specific. Target enrollment is 21 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Sidney Kimmel Cancer Center at Thomas Jefferson University
Thomas Jefferson University
Timeline & Enrollment
N/A
Nov 11, 2013
Jul 14, 2016
Primary Outcome
Change in peripheral blood T cell proliferation (stimulation) and cytokine production in vitro
Summary
This pilot research trial studies the response in blood cells to AMP-514, a drug shown to
 increase immune response (capacity to fight against infections and cancer) against cancer in
 patients with solid tumors undergoing radiotherapy. Measuring changes in biomarkers may help
 doctors decide if AMP-514 should be combined with radiotherapy and when is the best time to
 combine the drug with radiation.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT02153151
Non-Device Trial